Improving participation in HIV clinical trials: Impact of a brief intervention

HIV Clinical Trials

Volumn 2, Issue 3, 2001, Pages 205-212

  Freedberg, K A ^a   Sullivan, L ^a   Georgakis, A ^a   Savetsky, J ^a   Stone, V ^a   Samet, J H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Clinical trials; Human immunodeficiency virus; Participation

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BISEXUALITY; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RESEARCH; OUTPATIENT; PATIENT ATTITUDE; PATIENT EDUCATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE;

EID: 0034960429     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/PHB6-2EYA-GA06-6BP7     Document Type: Article

References (32)

1. Prevalence of HIV infection in the United States, 1984 to 1992
2. Scope of the AIDS epidemic in the United States
3. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
4. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
6. Differences in participation in experimental drug trials among persons with AIDS
7. Women and HIV/AIDS research
8. Interest in HIV vaccines among injection drug users in Baltimore, Maryland
9. Representation of American blacks in clinical trials of new drugs
10. Establishing a community network for recruitment of African Americans into a clinical trial. The African-American antiplatelet stroke Prevention Study (AAASPS) experience
11. The recruitment triangle: Reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial. An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS)
12. How preliminary data affect people's stated willingness to enter a hypothetical randomized controlled trial
13. Attitudes and beliefs of African Americans toward participation in medical research
14. Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment
15. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: A cross-sectional study in a municipal hospital clinic
16. Adherence and antiretroviral therapy in injection drug users
17. AIDS in intravenous drug users: Issues related to enrollment in clinical trials
18. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort
19. A model clinic for the initial evaluation and establishment of primary care for persons infected with human immunodeficiency virus
20. Determinants of accrual of women to a large, multicenter clinical trials program of human immunodeficiency virus infection
21. The challenge of minority recruitment in clinical trials for AIDS
22. Enrollment of drug abusers in HIV clinical trials: A public health imperative for communities of color
23. Barriers to clinical trials. Part II: Knowledge and attitudes of potential participants
24. The exclusion of non-English-speaking persons from research
25. Building a new consensus: Ethical principal and policies for clinical research on HIV/AIDS
26. The Tuskegee Syphilis Study, 1932 to 1972: Implications for HIV education and AIDS risk education programs in the black community
27. A legacy of distrust: African Americans and medical research
28. General considerations for the clinical evaluation of drugs
29. The regulation of investigational drugs
30. Historical background of clinical trials involving women and minorities
31. Women in clinical trials of new drugs. A change in Food and Drug Administration policy